30th Sep 2025 13:06
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:
----------
GENinCode PLC - Oxford-based genetic testing company focused on cardiovascular disease and ovarian cancer - Warns of full-year revenue below expectations, despite on-year growth. Pretax loss for the six months ended June 30 widens to GBP3.0 million from GBP2.4 million the previous year. Revenue rises 15% to GBP1.6 million from GBP1.4 million, led by the Spanish division, where first-half sales advance to GBP1.0 million from GBP912,000. Adjusted earnings before interest, taxation, depreciation and amortisation amount to a loss of GBP2.1 million, broadly stable on-year. Attributable loss per share narrows to 1.19 pence from 1.37p. The firm lowers annual revenue guidance to around GBP3.3 million "with similar levels of cost in the second half". It still expects growth on-year, albeit less marked than the "significant increase" it implied back in June, when it posted GBP2.7 million in revenue for 2024. GENinCode notes "slower than expected growth" in NHS contract business as a result of restructuring. The firm also points to delays in securing a De Novo risk classification from the US Food & Drug Administration for its Cardio inCode-Score test. It aims to submit a De Novo application in the first quarter of 2026, and says discussions with possible commercial partners continue.
----------
Genflow Biosciences PLC - London-based biotechnology firm, with research facilities in Belgium - Posts a wider pretax loss but pegs its hopes on 2026 being a "pivotal" year. Pretax loss widens to GBP737,618 during the first half of 2025 from GBP524,259 a year earlier, as Genflow books a GBP31,075 loss on currency translations, widened from GBP8,652 the previous year, while operating income declines to GBP245,107 from GBP792,109. The firm maintains having made "important progress" in both its human and animal health segments, noting "approvals of two new therapies including GLP-1 agonists" for patients with metabolic dysfunction-associated steatohepatitis. Within the next five months, it expects initial trial data for the use of its SIRT6 treatment in ageing canines.
----------
Ovoca Bio PLC - Dublin-based biopharmaceutical company - Says its pretax loss for the first half of 2025 remains largely unchanged from the year prior at EUR1.2 million, with no revenue generated in either year. Ovoca's cash balance stands at EUR1.5 million as of June 30, down from EUR2.9 million on-year. Back in May, the company signed a conditional letter of intent to acquire Tadeen International Ltd, a UK company with "a portfolio of mineral exploration licenses in Morocco prospective for copper and silver". Ovoca says it continues working to complete the purchase, and will update further "in due course".
----------
Tissue Regenix PLC - Leeds, England-based regenerative medical devices firm - Posts lower revenue on-year after a first-half sales slump. Revenue declines 6.1% to USD13.8 million from USD14.7 million. Pretax loss for the six months ended June 30 widens significantly to USD1.0 million from USD63,000, while loss per share on continuing operations widens to 1.34 US cents from 0.54 cents. The firm's cash position is USD1.1 million as of June 30, compared to USD1.9 million at the end of 2024. Earlier this month, Tissue Regenix noted a slowdown in orders from its partners due to macroeconomic uncertainty. Chief Executive Daniel Lee comments: "Although we have seen a downturn in trading in H1, with a resultant impact on our cash position, we remain confident in the underlying business and market opportunities for our leading products and superior technology. We expect both trading and cash to improve in the longer-term and our focus is to deliver sustainable revenue."
---------
Solvonis Therapeutics PLC - London-based biopharmaceutical company focused on addiction and mental health disorders - Reports a pretax loss of GBP1.6 million for first half of 2025, widened from GBP469,000 the previous year. Its cash balance rises to GBP1.7 million as of June 30, from GBP27,000 on-year, while net assets at the end of June amounted to GBP6.9 , more than doubled from GBP3.1 million at the end of December. The firm hails the "transformational step" of acquiring Awakn Life Sciences, a Canadian clinical-stage biotechnology firm, also focused on addiction and mental health, for a total purchase price of GBP3.7 million in May. Solvonis booked a GBP1.9 million loss on liabilities acquired though Awakn has added GBP5.6 million in total intangible assets. Solvonis says the integration process is underway, but it expects the enlarged company to continue to be loss-making "for the forseeable future" as it remains pre-revenue.
----------
By Holly Munks, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
GenincodeTissue Regenix GroupGenflow BiosciSolvonis TherapOvoca Bio